AMPEL BioSolutions

AMPEL BioSolutions

Harnessing Data to Improve Lives through Genomics

Founded 2013

Charlottesville, United States 28 employees Debt Financing Total: $14.31M Biotechnology, Health Care

AMPEL BioSolutions is a biomedical company founded in 2013, with headquarters in the United States. The company's slogan, "Harnessing Data to Improve Lives through Genomics", encapsulates its dedication to leveraging data and clinical science to drive advancements in personalized medicine. AMPEL's focus is on identifying and validating drug targets, with a commitment to finding the right drug for the right patient at the right time. This approach positions the company at the forefront of the next generation of novel therapies, addressing the challenges of research, discovery, and development. The company's multifaceted approach, integrating data-driven methodologies with clinical expertise, sets it apart in the biomedical field. AMPEL's team brings together a comprehensive understanding of biomedical sciences, basic/clinical research, medicine, and risk management, enabling them to creatively and efficiently tackle complex challenges and deliver tailored solutions. This unique combination positions AMPEL as a critical partner in advancing precision medicine and personalized treatment strategies. As AMPEL BioSolutions continues to drive innovation in genomics and personalized medicine, it presents an intriguing opportunity for venture capital investment. With its focus on addressing unmet medical needs and advancing the next generation of therapeutic solutions, AMPEL aligns with the growing demand for precision medicine technologies and tailored treatment approaches. The company's commitment to leveraging data and clinical expertise to improve patient outcomes positions it as a compelling prospect for investors seeking to support groundbreaking advancements in the biomedical and healthcare sectors.

Funding Stage	Amount	Investors	Lead Investors	Date
Debt Financing	$1.80M	-		06 Jul 2023
Debt Financing	$1.11M	-		13 Dec 2022
Convertible Note	$2.40M	-		15 Mar 2021
Convertible Note	$2.10M	-		29 Jan 2021
Pre Seed Round	$1.00M	-		01 Jan 2021
Pre Seed Round	$2.80M	1	U.S. Small Business Administration	01 Mar 2020
Grant	$3.10M	-		01 Jan 2019

Funding Stage

Amount

Investors

Lead Investors

Date

Debt Financing

$1.80M

06 Jul 2023

Debt Financing

$1.11M

13 Dec 2022

Convertible Note

$2.40M

15 Mar 2021

Convertible Note

$2.10M

29 Jan 2021

Pre Seed Round

$1.00M

01 Jan 2021

Pre Seed Round

$2.80M

U.S. Small Business Administration

01 Mar 2020

Grant

$3.10M

01 Jan 2019

FAQ About AMPEL BioSolutions

Harnessing Data to Improve Lives through Genomics

AMPEL BioSolutions was founded in 2013.

AMPEL BioSolutions is headquartered in Charlottesville, United States.

AMPEL BioSolutions operates in Biotechnology and Health Care. Its work centres on Genomics Solutions, Biomedical Company, Drug Target Identification and Clinical Trials.

AMPEL BioSolutions has approximately 28 employees.

AMPEL BioSolutions has completed 7 funding rounds, raising a total of $14.31M. The latest funding stage is Debt Financing.

Top alternatives and competitors to AMPEL BioSolutions include Molecular Health, Genelabs Technologies, Anthera Pharmaceuticals, Embleema, hVIVO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

AMPEL BioSolutions and Molecular Health are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About AMPEL BioSolutions

Funding Rounds & Investors (7)

AMPEL BioSolutions Alternatives & Competitors

FAQ About AMPEL BioSolutions